Defence Therapeutics Inc

XCNQ:DTC (Canada)  
C$ 1.57 (+7.53%) Apr 16
At Loss
Market Cap:
C$ 71.34M ($ 51.62M)
Enterprise V:
C$ 72.50M ($ 52.46M)
Volume:
68.27K
Avg Vol (2M):
20.86K
Also Trade In:
Volume:
68.27K
At Loss

Business Description

Description
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Name Current Vs Industry Vs History
Cash-To-Debt 0.23
Equity-to-Asset -3.43
Debt-to-Equity -0.66
Debt-to-EBITDA -0.13
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 56.93
9-Day RSI 49.65
14-Day RSI 46.21
6-1 Month Momentum % -40.27
12-1 Month Momentum % -53.95

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.18
Quick Ratio 0.18
Cash Ratio 0.12

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield % -7.31
Name Current Vs Industry Vs History
ROA % -810.52
ROIC % -2440.38
ROC (Joel Greenblatt) % -17639.54
ROCE % -3054.11

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -6.25
EV-to-EBITDA -6.26
EV-to-FCF -15.16
Earnings Yield (Greenblatt) % -15.99
FCF Yield % -6.5

Financials

XCNQ:DTC's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Defence Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$)
EPS (TTM) (C$) -0.27
Beta 0
Volatility % 29.89
14-Day RSI 46.21
14-Day ATR (C$) 0.104114
20-Day SMA (C$) 1.603
12-1 Month Momentum % -53.95
52-Week Range (C$) 1.21 - 3.74
Shares Outstanding (Mil) 45.44

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Defence Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Defence Therapeutics Inc Stock Events

Financials Calendars
Event Date Price(C$)
No Event Data

Defence Therapeutics Inc Frequently Asked Questions

What is Defence Therapeutics Inc(XCNQ:DTC)'s stock price today?
The current price of XCNQ:DTC is C$1.57. The 52 week high of XCNQ:DTC is C$3.74 and 52 week low is C$1.21.
When is next earnings date of Defence Therapeutics Inc(XCNQ:DTC)?
The next earnings date of Defence Therapeutics Inc(XCNQ:DTC) is .
Does Defence Therapeutics Inc(XCNQ:DTC) pay dividends? If so, how much?
Defence Therapeutics Inc(XCNQ:DTC) does not pay dividend.

Press Release

Subject Date
No Press Release